source
- Pfizer signs $500M deal with Enodia to develop Sec61 protein degradersPfizer has entered a licensing and research collaboration with Enodia Therapeutics, valued at up to $500 million, to discover and develop inhibitors of the Sec61 protein‑translocation channel. The…
- TRexBio raises $117 million in IPO as Retension secures $45 million Nasdaq debut for hypertension therapyTRexBio completed its initial public offering on Thursday, pricing the shares at a level that generated about $116.7 million in gross proceeds. The funding will support the company’s development of…